drugset / Trial / NCT00006052
STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
Treatment
Summary
RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia. PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have accelerated phase chronic myelogenous leukemia.
Timeline
- Start
- 2000-06
- Primary completion
- 2003-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | — | Oral |